GLP-1 receptor agonists (often called GLP-1s) are best known for their role in diabetes and weight management. More recently, they have drawn attention for their potential impact on cravings, impulse control, and compulsive behaviors.
At The Meadows, we are committed to responsible innovation and are carefully exploring this emerging area. GLP-1s are not intended for most patients in addiction treatment, but may offer benefit for a carefully selected subset of individuals when used within comprehensive care. The science is still developing, and while we are excited to offer this cutting-edge treatment to our patients who would benefit, our focus remains on safe, thoughtful integration and transparency about what is known and what is still being studied.
Why GLP-1s for Addiction Treatment?
Addiction is associated with changes in the brain’s reward and motivation systems that can intensify cravings and narrow a person’s ability to pause and reflect.
Early research suggests GLP-1s may influence these same systems. By acting on brain pathways involved in reward and impulse control, GLP-1s may help reduce the intensity and urgency of cravings across a range of addictive behaviors.
Clinicians describe this effect as turning down the noise of addiction. For some individuals, urges feel less constant and less overwhelming, making it easier to engage in therapy and recovery work.
This research is still expanding, with much of the current evidence coming from preclinical studies and Phase 2 and Phase 3 clinical trials.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are medications originally developed to treat type 2 diabetes and later approved for weight management. They include medications such as semaglutide and liraglutide, which are commonly known by brand names like Ozempic, Wegovy, and Saxenda.
In the body, GLP-1s:
- Support blood sugar regulation
- Slow digestion
- Increase feelings of fullness
Researchers have also identified GLP-1 receptors in areas of the brain involved in reward, motivation, and decision-making, which is why they are being studied in addiction treatment.
Beyond their role in addiction, GLP-1 receptor agonists are used in a range of medical conditions, including type 2 diabetes, obesity, cardiovascular disease, liver and kidney health, and emerging research in neurodegenerative disorders. This broad impact highlights why GLP-1s are a focus of ongoing clinical innovation and study.
Promising Early Insights in Craving Reduction
Alongside formal research, early clinical observations suggest some individuals may experience:
- Fewer intrusive or persistent cravings
- Less mental preoccupation with substances or compulsive behaviors
- Greater ability to pause before acting on urges
Some clinicians are also observing fewer “transfer” or “jumping” behaviors, where one addiction is replaced by another. While this observation is not yet supported by definitive data, it is an important area of ongoing monitoring and study.
How GLP-1s Fit Into Treatment at The Meadows
GLP-1s are not a standalone treatment for addiction. Medication alone does not resolve trauma, rebuild coping skills, or address the emotional and relational drivers of substance use.
When appropriate, GLP-1s may serve as a supportive tool within comprehensive care by:
- Reducing early relapse risk
- Increasing emotional and cognitive capacity for therapy
- Supporting engagement in treatment
At The Meadows, any consideration of GLP-1s is paired with trauma-focused therapy, behavioral recovery work, nutritional support, and close medical and psychiatric oversight.
Starting a GLP-1 Is a Serious, Ongoing Commitment
GLP-1 receptor agonists are not casual or short-term interventions. For many individuals, meaningful benefit may require long-term or lifelong use, similar to other maintenance medications used in chronic conditions.
Beginning a GLP-1 often brings changes that extend beyond cravings or appetite. Patients may notice shifts in how they experience hunger, reward, motivation, and even how others respond to their bodies and behaviors. These changes can affect identity, self-image, and relationships, especially for individuals with a history of shame, stigma, or disordered eating.
At The Meadows, we help patients prepare for these realities. Starting a GLP-1 includes thoughtful conversations about expectations, values, and the kind of recovery journey a patient wants to support. This reflective process is part of the therapeutic container we create around any medication with the potential to shape long-term behavior and self-perception.
Who May Benefit and Who May Not
GLP-1s are appropriate only for a subset of individuals with substance use disorders. Many patients will not be candidates for this treatment, and that determination is made intentionally, not by default.
Eligibility depends on multiple factors, including medical history, psychiatric stability, nutritional status, recovery stage, and the presence of eating disorder symptoms or vulnerabilities. For some individuals, the risks of appetite suppression, weight-focused thinking, or misuse outweigh potential benefits.
Our approach prioritizes suitability over novelty, carefully considering whether a medication is right for each patient.
Committed to Patient Safety
Screening and Eating Disorder Risk
GLP-1s are not appropriate for every individual with a substance use disorder, and careful screening is essential.
While these medications may offer meaningful support for some patients, they are intended for a specific subset of individuals whose medical history, nutritional status, and recovery needs align with this approach. GLP-1s suppress appetite and alter hunger cues, which means they carry real risks for individuals with certain medical conditions or a history of eating disorders.
Because GLP-1s suppress appetite and alter hunger cues, careful screening is essential.
Individuals with restrictive eating disorders, fasting behaviors, or weight-driven purging may be at increased risk of symptom reactivation and are not appropriate candidates. Even among individuals without an eating disorder history, close nutritional monitoring is required to ensure adequate nourishment and to prevent unintended physical or psychological harm.
This is why GLP-1 integration at The Meadows is selective, individualized, and grounded in multidisciplinary evaluation. Nutrition support and a non-restrictive, balanced approach to eating are essential components of any responsible use of these medications.
Medical and Psychological Monitoring
GLP-1s are only appropriate for individuals who are medically and psychologically stable. These medications do not treat acute psychiatric conditions and require ongoing monitoring for side effects, mood changes, and overall well-being.
A Measured, Evidence-Informed Approach
The Meadows is taking a measured approach to GLP-1 integration:
- The science is promising, but still early
- Patient safety guides every decision
- Screening, monitoring, and interdisciplinary care are essential
- Medication is always paired with comprehensive treatment
As research evolves, our approach will continue to be refined. We are committed to transparency with patients, families, and partners about what is known today and what is still being learned.
What’s Next in the Research
Multiple Phase 2 and Phase 3 clinical trials are exploring the role of GLP-1s in alcohol use disorder, substance use disorders, and binge-type eating behaviors.
While it is too early to draw definitive conclusions, GLP-1s represent a meaningful area of innovation at the intersection of neurobiology, metabolism, and addiction medicine.
Getting Started With Care
- GLP-1s may help reduce cravings by influencing brain reward pathways
- Early research and clinical observations are encouraging, but not conclusive
- These medications are adjunctive tools, not cures
- Careful screening, especially related to eating disorders, is essential
- A cautious, closely monitored approach is required
If you have questions about addiction treatment at The Meadows, our team is here to help guide you with treatment programs that are thoughtful, evidence-informed, and individualized. Contact us today to learn more.
